VENOUS THROMBO-EMBOLISM (VTE) PROPHYLAXIS AMONG KING ABDULAZIZ UNIVERSITY HOSPITAL (KAUH) ONCOLOGICAL PATIENTS, A CROSS SECTIONAL SNAPSHOT

¹Bassim Albeirouti, ²Ameerh Meshael ALRobai, ³Rayan Nasser ALharthi, ⁴Hamza Mohammed S. AlQadi, ⁵Anas Mohammed S. AlQadi

¹MD, MSc, CIP, FARCPC, FACP, ²TU Intern, ³TU Intern, ⁴TU CMMS 6th Y, ⁵TU Intern

Abstract: One of the most common & potentially destructive complications that can occur among oncological patients is venous thromboembolism (VTE), so, prevention of (VTE) is essential for most admitted patients. There are updated recommendations that have been provided by the 9th edition of American collage of Chest Physicians (ACCP) clinical practice guidelines for prevention & treatment for the subgroup of patients in each department that confirm the evaluation of patient risk for VTE. The aim of this study is quality improvement to evaluate the commitment of King Abdulaziz University hospital (KAUH), department of Surgery, division of oncology to the international recommendations of the ACCP using a cross sectional snapshot analysis.

Research methodology: In the month of October 2015 the research project was developed by a research group using a cross sectional snapshot analysis. The forms of data collection were derived from the 9th ACCP guidelines and were used to evaluate the division of oncology adherence to ACCP guidelines. The data was collected by the research group. The ethic approval of the study was obtained from the chairman ethics committee.

Main results: In the month of October 2015 a cross sectional snapshot analysis showed that 4 out of 15 (26.6%) patients who were admitted during this period were on VTE prophylaxis.

Keywords: (VTE) PROPHYLAXIS AMONG (KAUH) ONCOLOGICAL PATIENTS.

I. INTRODUCTION

When a clot forms in a vein and limits blood flow through this vein, this is called venous Thrombi-Embolism (VTE). Each year about 300,000 people die due to complications from deep vein thrombosis (DVT) or pulmonary embolism (PE), which are collectively referred to by the broader term as VTE. For such a high incidence complication that may reach up to 40% (1), thrombo-prophylaxis is recommended. Prevention of VTE is essential for most admitted patients. The American College of Chest Physicians (ACCP) developed guidelines for the prevention of VTE that are updated regularly every 3 to 4 years. In all VTE prophylaxis patients with cancer are considered among high-risk group due to cancer itself, or cancer treatment. Most of the recommendations in this guideline are based on low-quality evidence limited by small samples, incomplete blinding, unclear concealment of treatment allocation, and measurement of surrogate outcomes. Randomized trials are needed to enrol representative samples (ideally in community settings) and be adequately powered to show the differences. The goal of this study is quality improvement to evaluate the commitment of King Abdul-Aziz University Hospital (KAUH), department of Surgery, Division of ONCOLOGY to the international recommendations of the ACCP using a cross sectional snapshot analysis, and to compare the result of this study between the year of 2011, 2013, and 2015 to see if there is any improvement [1].

International Journal of Healthcare Sciences ISSN 2348-5728 (Online)

Vol. 4, Issue 2, pp: (1105-1108), Month: October 2016 - March 2017, Available at: www.researchpublish.com

II. OBJECTIVES OF THIS STUDY

As a quality improvement project this study aims are:

- 1- To assess level of adherence of KAUH to ACCP with respect to VTE Prophylaxis for ONCOLOGY patients.
- 2- To assess the number of oncological patients who are on VTE Prophylaxis.
- 3- To compare the current results with a similar project carried out in 2011 and 2013 addressing same items and assess if there is any improvement.

III. METHODS

A group of students with their supervisor started the project at KAUH as a cross sectional snap shot analysis. A case report form (CRF) has been developed from the 9th edition of ACCP guidelines as a check list. Data were collected and analyzed.

The following is the CRF utilized in the study:
1- Is there a formal active KAUH Strategy for VTE Prophylaxis?
□ Yes □ NO
2- Is there a written institution policy at KAUH addressing VTE Prophylaxis?
□ Yes □ NO
3- Are there strategies to increase thrombo-prophylaxis adherence at KAUH?
a. Computer Decision Support System
□Yes □NO
b. Preprinted Orders
□Yes □NO
c. Periodic Audit & Feedback
□Yes □NO
4- Is there a KAUH Divisions of Gyne-Oncology, Medical Oncology, & Surgical Oncology formal active Strategy fo VTE Prophylaxis?
□Yes □NO
5- Are there strategies to increase thrombo-prophylaxis adherence in the Department of Surgery at KAUH?
a. Computer Decision Support System
□Yes □NO
b. Preprinted Orders
□Yes □NO
c. Periodic Audit & Feedback
□Yes □NO
6- Are there passive methods such as distribution of educational materials or educational meetings of VTE Prophylaxis as sole strategies to increase adherence to guidelines?
□ Yes □ NO
7- Is there any surgical patient who is on Aspirin alone as VTE Prophylaxis?
□Yes □NO
8- Is Inferior Vena Cava (IVC) Filter is used as VTE prophylaxis in patients with cancer?
□Yes □NO
9- Is there any approved mechanical method of VTE Prophylaxis among patients with cancer, 1st Intermittent Pneumonic Compression (IPC)?
□Yes □NO

International Journal of Healthcare Sciences ISSN 2348-5728 (Online)

Vol. 4, Issue 2, pp: (1105-1108), Month: October 2016 - March 2017, Available at: www.researchpublish.com

10-Is it used correctly by physicians?
□Yes □NO
11-Is it used correctly by nurses?
□Yes □NO
12-Is it used per-operatively (Pre-OP, Intra-OP, Post-OP)?
$Pre OP: \Box Yes \ \Box NO, Intra-OP: \Box Yes \ \Box NO, Post-OP: \Box Yes \ \Box NO$
13-Is it used alone (i.e. in high risk of bleeding patients)?
□ Yes □ NO
14-Is it used in combination with chemical prophylaxis (i.e. in high risk of thrombosis patients)?
□Yes □NO
15-Is there any approved mechanical method of VTE Prophylaxis among patients with cancer, 2nd Gradual Compression Stocking (GCS)?
□Yes □NO
16-Is it used correctly by physicians?
□Yes □NO
17-Is it used correctly by nurses?
□Yes □NO
18-Is it used per-operatively (Pre-OP, Intra-OP, Post-OP)?
OP: \Box Yes \Box NO, Intra-OP: \Box Yes \Box NO, Post-OP: \Box Yes \Box NO
19-Is it used alone (i.e. in high risk of bleeding patients)?
□ Yes □ NO
20-Is it used in combination with chemical prophylaxis (i.e. in high risk of thrombosis patients)?
□ Yes □ NO
21-Is Doppler Ultra Sound (DUS) is used as a screening method among KAUH PATIENTS WITH CANCER patients?
□ Yes □ NO
Is there a Risk Assessment Model (RAM) used to stratify patient's thrombotic risk?
□ Yes □ NO

IV. RESULTS

In the month of October 2015, a group of Student Investigator Program (SIP) with the director and supervisor carried out a quality improvement project titled with "Protect our Patients from VTE" using a cross sectional snapshot analysis to assess the adherence of VTE prophylaxis among Oncological Patients in the Division of Oncology. The Level of Adherence of Oncology Division in The department of Surgery 4 out of 15 patients who were admitted during this period were on VTE prophylaxis (26.6%).

Item/Department	Level of Adherence in 2015		Level of Adherence in 2011	Patients on VTE Prophylaxis in 2015	VTE	Patients on VTE Prophylaxis in 2011
Oncology	4/15 (26.6%)	14/18 (77.7%)	11/28 (39.2%)	4/15	13/16	7/9

V. DISCUSSION

Apparently, there is an improvement in the division of Oncology at KAUH in the level of adherence to ACCP guidelines for VTE prophylaxis and in the percentile of patients with Oncological disorders who are on VTE prophylaxis. Our Recommendation as shown in table:

International Journal of Healthcare Sciences ISSN 2348-5728 (Online)

Vol. 4, Issue 2, pp: (1105-1108), Month: October 2016 - March 2017, Available at: www.researchpublish.com

condition	High risk of bleeding	Low risk of bleeding	High risk of thrombosis	Low risk of thrombosis	Recommendation
Prostate	Yes				Pharmacologic prophylaxis
Cancer					
Lung Cancer			Yes		Mechanical prophylaxis+ pharmacologic Prophylaxis
Non Hodgkin lymphoma	yes				Mechanical prophylaxis or unfractionated Heparin, or LMWH
Acute lymphocytic leukemia			Yes		Mechanical prophylaxis+ pharmacologic Prophylaxis
T cell lymphoma					Pharmacologic Prophylaxis
Chronic myeloid leukemia	Yes				Mechanical prophylaxis
Malignant tumor –giant cell type			Yes		Pharmacologic Prophylaxis+ mechanical prophylaxis
Stomach Cancer	Yes		Yes		Pharmacologic Prophylaxis+ mechanical prophylaxis
HCC			Yes		Pharmacologic Prophylaxis+ mechanical prophylaxis
Neoplasm of base of the tongue				Yes	Mechanical prophylaxis
Small intestine neoplasm	Yes		Yes		Mechanical prophylaxis or unfractionated Heparin, or LMWH
Colo-rectal Cancer	Yes		Yes		Mechanical prophylaxis or unfractionated Heparin, or LMWH
Squamous cell carcinoma of mouth				Yes	Mechanical prophylaxis
Malignant neoplasm of cheek muscle				Yes	Mechanical prophylaxis
Carcinoid tumor of uncertain	Yes		Yes		Mechanical prophylaxis or unfractionated Heparin, or LMWH

VI. CONCLUSIONS

Using a cross sectional snapshot analysis, to assess the adherence of Oncology division in the department of Surgery at KAUH, to the ACCP guidelines for VTE prevention of the data showed that there is no improvement to the adherence to ACCP guideline. The importance of Required Organizational Practices (ROP), the quality department and administration are already in the process of implementing VTE prophylaxis. We should repeat the study in future with implementing VTE risk assessment Model and criteria.

REFERENCES

1- Gould, M.K., et al., Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012. 141(2 Suppl): p. e227S-77S.